Relmada Therapeutics, Inc. (RLMD) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -15.07M | -14.6M | -6.72M | -6.4M | -18.07M | -8.8M | -16.66M | -13.26M | -13.04M | -10.25M | -11.63M | -13.27M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 16.6% | -65.87% | 59.64% | 51.73% | -38.59% | 14.15% | -43.21% | 0.08% | 21.01% | 71.44% | 56.7% | 38.62% |
| Net Income | -19.05M | -19.87M | -10.09M | -9.87M | -17.56M | -18.66M | -21.73M | -17.77M | -21.83M | -25.17M | -22M | -25.3M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 3.21M | 3.61M | 3.47M | 4.48M | 6.72M | 7.96M | 7.21M | 8.3M | 9.89M | 11.39M | 11.17M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 4.18M | 827.11K | -4.96M | -33.41K | -218.68K | 236.22K | -426.39K | -87.65K | -103.85K | -404.94K | 630.86K | 639.63K |
| Working Capital Changes | -199.33K | 1.23M | 4.72M | 24.91K | -4.77M | 2.9M | -2.47M | -2.62M | 599.76K | 5.43M | -1.65M | 220.53K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.76M | 115.84K | 91.19K | 96.9K | -2.87M | 1.79M | -1.83M | -1.01M | 1.68M | 649.26K | -2M | 431.65K |
| Cash from Investing | -135.23M | -76.93M | 6.75M | 6.68M | 15.36M | 11.35M | 16.14M | 14.01M | 10.06M | 7.74M | 3.86M | -1.15M |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 156.57M | 93.64M | 0 | -73.02K | 0 | -172.49K | -89.6K | 0 | 221.75K | -98.46K | 0 | 0 |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 156.64M | 93.64M | 0 | 0 | 0 | 0 | 0 | 0 | 246.75K | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -65.65K | 0 | 0 | -73.02K | 0 | -172.49K | -89.6K | 0 | -25K | -98.46K | 0 | 0 |
| Net Change in Cash | 6.28M | 2.11M | 31.13K | 203.65K | -2.71M | 2.37M | -602.47K | 751.24K | -2.76M | -2.61M | -7.77M | -14.43M |
| Free Cash Flow | -15.07M | -14.6M | -6.72M | -6.4M | -18.07M | -8.8M | -16.66M | -13.26M | -13.04M | -10.25M | -11.63M | -13.27M |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 16.6% | -65.87% | 59.64% | 51.73% | -38.59% | 14.15% | -43.21% | 0.08% | 21.01% | 71.44% | 56.7% | 38.62% |
| FCF per Share | -0.17 | -0.21 | -0.20 | -0.19 | -0.59 | -0.29 | -0.55 | -0.44 | -0.43 | -0.34 | -0.39 | -0.44 |
| FCF Conversion (FCF/Net Income) | 0.79x | 0.73x | 0.67x | 0.65x | 1.03x | 0.47x | 0.77x | 0.75x | 0.60x | 0.41x | 0.53x | 0.52x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |